Protalix BioTherapeutics, Inc. — Operating Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1bfddec1-74e4-409d-8748-86c3c7e158f7/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-5.5M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-029858 |
| FY 2024 | $3.9M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003039 |
| FY 2023 | $10.5M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-003161 |
| FY 2022 | $-13.0M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002102 |
| FY 2021 | $-20.5M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004823 |
| FY 2020 | $2.7M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003681 |
| FY 2019 | $-10.7M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-032540 |
| FY 2018 | $-19.3M | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-014464 |
| FY 2017 | $-34.5M | 2017-01-01 – 2017-12-31 | evidence 0001144204-19-014464 |
| FY 2016 | $-33.2M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-015083 |
| FY 2015 | $-23.7M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-086642 |
| FY 2014 | $-28.6M | 2014-01-01 – 2014-12-31 | evidence 0001144204-16-086642 |
| FY 2013 | $-34.1M | 2013-01-01 – 2013-12-31 | evidence 0001144204-16-086642 |
| FY 2012 | $-12.2M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-012065 |
| FY 2011 | $-36.5M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-011082 |
| FY 2010 | $-30.0M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-011082 |
| FY 2009 | $-32.0M | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-011082 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Protalix BioTherapeutics, Inc. — all facts · Revenue · Net Income